US FDA adds label warning to J&J’s and Legend Biotech’s cancer therapy

Investing.comMonday, October 13, 2025 at 1:42:24 AM
US FDA adds label warning to J&J’s and Legend Biotech’s cancer therapy
The US FDA has issued a label warning for the cancer therapy developed by Johnson & Johnson and Legend Biotech, highlighting potential risks associated with the treatment. This development is significant as it raises concerns about patient safety and could impact the therapy's usage in clinical settings. The warning may lead to increased scrutiny from healthcare providers and patients alike, emphasizing the importance of thorough communication regarding treatment options.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
US FDA adds boxed warning to J&J, Legend Biotech’s cancer therapy
NegativeFinancial Markets
The US FDA has issued a boxed warning for the cancer therapy developed by Johnson & Johnson and Legend Biotech, highlighting serious risks associated with its use. This warning is significant as it alerts healthcare providers and patients to potential severe side effects, which could impact treatment decisions and patient safety. The move underscores the importance of monitoring drug safety and ensuring that patients are fully informed about the risks involved in their treatment.
FDA approves Teva's UZEDY for bipolar I disorder maintenance
PositiveFinancial Markets
The FDA has approved Teva's UZEDY for the maintenance treatment of bipolar I disorder, marking a significant advancement in mental health care. This approval is crucial as it provides patients with a new option to manage their condition effectively, potentially improving their quality of life. With bipolar disorder affecting millions, UZEDY's introduction could lead to better treatment outcomes and support for those struggling with this challenging disorder.
Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says
PositiveFinancial Markets
Johnson & Johnson is reportedly in discussions to acquire Protagonist Therapeutics, a move that could significantly enhance its portfolio in the pharmaceutical sector. This acquisition is important as it reflects J&J's strategy to bolster its research and development capabilities, particularly in innovative therapies. If successful, this deal could lead to new treatments and advancements in healthcare, benefiting patients and investors alike.
Johnson & Johnson in Talks to Buy Protagonist Therapeutics
PositiveFinancial Markets
Johnson & Johnson is in discussions to acquire Protagonist Therapeutics, a move that could significantly enhance their collaboration on a treatment for ulcerative colitis. This acquisition is important as it not only strengthens their existing partnership but also highlights the growing focus on innovative therapies in the healthcare sector.
Latest from Financial Markets
JPMorgan initiates StubHub stock with Overweight rating on market leadership
PositiveFinancial Markets
JPMorgan has initiated coverage of StubHub with an Overweight rating, highlighting the company's strong position in the ticket resale market. This endorsement is significant as it reflects confidence in StubHub's ability to lead in a competitive industry, potentially attracting more investors and boosting its stock performance. Such a positive outlook from a major financial institution can enhance StubHub's credibility and market presence.
Samsung set for highest Q3 profit in three years as AI demand lifts chip prices
PositiveFinancial Markets
Samsung is poised to report its highest third-quarter profit in three years, driven by a surge in demand for AI technologies that has boosted chip prices. This is significant as it highlights the growing importance of AI in the tech industry and how companies like Samsung are capitalizing on this trend to enhance their financial performance.
Blackstone considers possible bid for UK self-storage firm Big Yellow
PositiveFinancial Markets
Blackstone is reportedly eyeing a potential bid for the UK self-storage company Big Yellow, which could signal a significant investment move in the growing self-storage market. This interest highlights the increasing demand for storage solutions as urban living spaces shrink and consumer habits evolve. If the bid goes through, it could reshape the competitive landscape of the self-storage industry in the UK.
Shawbrook Bank plans London IPO in November as European listings surge
PositiveFinancial Markets
Shawbrook Bank is gearing up for an initial public offering (IPO) in London this November, riding the wave of a surge in European listings. This move is significant as it reflects growing investor confidence in the market and could pave the way for more companies to consider going public. Shawbrook's IPO is expected to attract attention and could be a key indicator of the health of the financial sector in Europe.
Microsoft’s SWOT analysis: cloud giant’s stock rides AI wave amid challenges
PositiveFinancial Markets
Microsoft is riding a wave of positivity as its stock benefits from advancements in artificial intelligence, despite facing some challenges. This growth highlights the company's strong position in the cloud market and its ability to innovate. Investors are optimistic about Microsoft's future, making it a key player to watch in the tech industry.
East Star Resources extends warrant expiry by 2.5 months
PositiveFinancial Markets
East Star Resources has announced an extension of the expiry date for its warrants by an additional 2.5 months. This decision is significant as it provides investors with more time to exercise their warrants, potentially leading to increased investment in the company. Such moves can enhance liquidity and investor confidence, which are crucial for the company's growth and stability.